Articles published by CytoDyn Inc.
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Today 8:30 EDT
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn to Host Webcast to Provide Company Update
May 28, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Announces FDA Has Lifted Clinical Hold
February 29, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
February 01, 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Announces Webcast to Provide Company Update
December 07, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
November 21, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
November 2023 Letter to Shareholders
November 03, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn to Hold Webcast to Provide a Company Update
April 05, 2023
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
December 23, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
November 22, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
October 28, 2022
From CytoDyn Inc.
Via GlobeNewswire
Tickers
CYDY
![](https://ml.globenewswire.com/media/41cd1342-b084-40b8-8ef3-c69f4bf02d3b/small/cytodyn-color-logo-no-r-png.png)
![](https://mms.businesswire.com/media/20220125006193/en/1323030/21/CYDY_logo.jpg)
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
![](https://mms.businesswire.com/media/20220113005331/en/1323030/21/CYDY_logo.jpg)
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
![](https://mms.businesswire.com/media/20220110005384/en/936017/4/CYTODYN+Logo.jpg)
![](https://mms.businesswire.com/media/20220105005661/en/935991/4/logo.jpg)
![](https://mms.businesswire.com/media/20211222005314/en/935806/4/5420039_cytodyn.jpg)
![](https://mms.businesswire.com/media/20211221005432/en/935777/4/5420040_cytodyn.jpg)
![](https://mms.businesswire.com/media/20211213005299/en/935528/4/5420039_cytodyn.jpg)
![](https://mms.businesswire.com/media/20211209005635/en/934757/4/5420039_cytodyn.jpg)
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
December 09, 2021
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
![](https://mms.businesswire.com/media/20211209005607/en/934796/4/5420039_cytodyn.jpg)
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
December 09, 2021
From CytoDyn Inc.
Via Business Wire
Tickers
CYDY
![](https://mms.businesswire.com/media/20211208005647/en/934357/4/Cytodyn.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.